WINTON GROUP Ltd Has $3.14 Million Position in Hologic, Inc. (NASDAQ:HOLX)

WINTON GROUP Ltd trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 38.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,526 shares of the medical equipment provider’s stock after selling 27,382 shares during the quarter. WINTON GROUP Ltd’s holdings in Hologic were worth $3,138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC grew its position in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the period. Boston Partners grew its holdings in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Nordea Investment Management AB increased its stake in Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Hologic in the fourth quarter valued at $27,007,000. Finally, Teacher Retirement System of Texas raised its holdings in shares of Hologic by 82.9% during the fourth quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider’s stock valued at $46,850,000 after purchasing an additional 294,538 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX stock opened at $62.32 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a market cap of $13.98 billion, a price-to-earnings ratio of 19.66, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The firm’s 50-day simple moving average is $65.41 and its two-hundred day simple moving average is $73.50.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on HOLX. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Evercore ISI lowered their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Finally, Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.